Collaboration Revenue: Collaboration revenue was $2.0 million for the second quarter of 2025, compared to $94.7 million for the same period in 2024. This decrease is primarily attributable to the ...

Cumberland Pharmaceuticals Inc (CPIX) reports a 10% revenue increase and strategic international expansions, despite facing ...

Get KSRA Praneeth News on Telangana Today, KSRA Praneeth latest news, KSRA Praneeth news, | Telangana Today ...

K.S.R.A. Praneeth, an 18-year-old battling Duchenne Muscular Dystrophy, competed in the World IPCA Chess Championship in Goa, ...

Cumberland Pharmaceuticals' Q2 2025 earnings highlight revenue growth, clinical progress in ifetroban for DMD, and Vibativ's global expansion.

Cumberland Pharmaceuticals Inc. ( NASDAQ: CPIX) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP & CFO Todd M.

Balance Sheet: At June 30, 2025, Cumberland had approximately $68 million in total assets, including $16 million in cash and cash equivalents. Liabilities totaled $40 million, including $5 million on ...

The FDA has granted breakthrough therapy designation to DYNE-251 for the treatment of DMD in patients amenable to exon 51 ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The Independent ...

The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.

Catalyst Pharmaceuticals CPRX is scheduled to report its second-quarter 2025 earnings results on Aug. 6, after market close.